Form 4: Elanco CEO Acquires Deferred Stock Units

Elanco Animal Health Inc's President and CEO, Jeffrey N. Simmons, acquired 125.0221 deferred stock units, increasing his beneficial ownership.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc. (ELAN), acquired 125.0221 Deferred Stock Units (DSUs).
• The transaction date for this acquisition is October 31, 2025.
• Each DSU represents the right to receive one share of Elanco common stock or its cash equivalent.
• The DSUs were acquired at a price of $22.15 per unit.
• Following this acquisition, Mr. Simmons beneficially owns a total of 18,224.6156 DSUs.
• These DSUs are scheduled to settle in cash or shares following termination of employment or during a specified future year, in accordance with the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The acquisition of deferred stock units by the CEO is generally a positive signal, indicating management's continued commitment and alignment with shareholder interests. It's a form of compensation that vests over time, reflecting confidence in the company's long-term prospects.

Positives

• Increased beneficial ownership by a key executive (President, CEO, and Director) signals confidence in the company's future prospects.
• The acquisition of deferred stock units aligns executive incentives with long-term shareholder value, as the units' value is tied to the company's stock performance.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the settlement terms of the deferred stock units.

Industry Context

This insider transaction is a routine disclosure for executive compensation and does not directly provide broader industry trends. However, executive stock acquisitions can be viewed positively as a sign of confidence in the animal health sector's future performance.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries.
• The acquisition of deferred stock units as part of executive compensation is a common practice, aligning executive interests with shareholder value, similar to practices at peer companies in the pharmaceutical and animal health sectors like Zoetis Inc. or IDEXX Laboratories, Inc.
• The specific amount and value are relative to Mr. Simmons' overall compensation package and Elanco's stock performance.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's financial interests with long-term shareholder value through deferred stock ownership.
• Employees: The Executive Deferral and Stock Match Plan provides a framework for executive compensation, potentially influencing broader compensation strategies.

Next Steps

• The deferred stock units will settle in cash or shares following termination of employment or during a specified future year, in accordance with the Executive Deferral and Stock Match Plan.

Key Dates

Recommendation

While the CEO's acquisition of deferred stock units is a positive signal of confidence and aligns executive interests with shareholders, it is a routine compensation event rather than an open-market purchase. This type of transaction typically reinforces a 'hold' position for existing investors, as it doesn't fundamentally alter the company's financial outlook or strategic direction in a way that would warrant a 'buy' or 'sell' recommendation based solely on this filing. It suggests stability and continued management commitment.

Keywords

Elanco Animal Health, ELAN, Jeffrey N. Simmons, Insider Transaction, Form 4, Deferred Stock Units, Executive Compensation, Stock Acquisition